Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses EWTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EWTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Koch | $670,000 | — | $1,171,625 | $5,041,621 | $462,300 | — | $14,000 | $7,359,546 |
| President and Chief Executive Officer | ||||||||
| Robert Blaustein | 525,000 | — | 999,475 | 2,801,305 | 227,605 | — | 14,000 | 4,567,385 |
| Former Chief Development Officer | ||||||||
| Michael Nofi | 67,813 | — | 799,750 | 3,387,209 | 29,887 | — | 0 | 4,284,659 |
| Chief Financial Officer | ||||||||
| Behrad Derakhshan | 520,000 | — | 401,700 | 1,728,428 | 269,100 | — | 14,000 | 2,933,228 |
| Chief Operating Officer | ||||||||
| Joanne Donovan | 530,358 | — | — | — | 243,965 | — | 14,000 | 2,785,306 |
| Chief Medical Officer | ||||||||
| Alan Russell | 499,580 | — | — | — | 229,807 | — | 8,479 | 2,734,849 |
| Co-Founder and Chief Scientific Officer | ||||||||
| R. Michael Carruthers | 465,694 | — | 392,707 | 1,500,845 | 214,219 | — | 14,000 | 2,587,465 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kevin Koch | $7,359,546 | $7,601,200 | $3,975,855 | −241,654 |
| Robert Blaustein | 4,567,385 | — | — | — |
| Michael Nofi | 4,284,659 | — | — | — |
| Behrad Derakhshan | 2,933,228 | 2,896,193 | 1,756,317 | +37,035 |
| Joanne Donovan | 2,785,306 | 2,924,474 | 1,716,844 | −139,168 |
| Alan Russell | 2,734,849 | — | — | — |
| R. Michael Carruthers | 2,587,465 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kevin Koch | RSU | 87,500 | — | $2,171,313 |
| Kevin Koch | RSU | 53,907 | — | 1,337,702 |
| Michael Nofi | RSU | 43,750 | — | 1,085,656 |
| Robert Blaustein | RSU | 30,000 | — | 744,450 |
| Behrad Derakhshan | RSU | 30,000 | — | 744,450 |
| Joanne Donovan | RSU | 28,125 | — | 697,922 |
| Alan Russell | RSU | 28,125 | — | 697,922 |
| R. Michael Carruthers | RSU | 26,875 | — | 666,903 |
| Robert Blaustein | RSU | 17,500 | — | 434,263 |
| R. Michael Carruthers | RSU | 17,344 | — | 430,391 |
| Kevin Koch | Option | 250,000 | 7.08 | — |
| Behrad Derakhshan | RSU | 17,344 | — | 430,391 |
| Joanne Donovan | RSU | 17,344 | — | 430,391 |
| Alan Russell | RSU | 17,344 | — | 430,391 |
| Kevin Koch | RSU | 41,545 | — | 0 |
| Kevin Koch | RSU | 178,711 | — | 0 |
| Alan Russell | RSU | 130,352 | — | 0 |
| Kevin Koch | Option | 91,667 | 10.39 | — |
| Kevin Koch | Option | 287,500 | 17.05 | — |
| Kevin Koch | Option | 481,250 | 13.39 | — |
| Michael Nofi | Option | 262,500 | 18.28 | — |
| Robert Blaustein | Option | 160,000 | 27.39 | — |
| Robert Blaustein | Option | 96,250 | 13.39 | — |
| R. Michael Carruthers | Option | 33,334 | 10.39 | — |
| R. Michael Carruthers | Option | 83,334 | 7.08 | — |
| R. Michael Carruthers | Option | 92,500 | 17.05 | — |
| R. Michael Carruthers | Option | 147,813 | 13.39 | — |
| Behrad Derakhshan | Option | 33,334 | 10.39 | — |
| Behrad Derakhshan | Option | 91,667 | 7.08 | — |
| Behrad Derakhshan | Option | 92,500 | 17.05 | — |
| Behrad Derakhshan | Option | 165,000 | 13.39 | — |
| Joanne Donovan | Option | 40,000 | 10.39 | — |
| Joanne Donovan | Option | 83,334 | 7.08 | — |
| Joanne Donovan | Option | 92,500 | 17.05 | — |
| Joanne Donovan | Option | 154,688 | 13.39 | — |
| Alan Russell | RSU | 1,147,365 | — | 0 |
| Alan Russell | Option | 36,667 | 10.39 | — |
| Alan Russell | Option | 83,334 | 7.08 | — |
| Alan Russell | Option | 92,500 | 17.05 | — |
| Alan Russell | Option | 154,688 | 13.39 | — |
The compensation committee aims to provide competitive compensation to attract and retain top talent, create a direct link between business plan achievement and employee compensation, motivate the achievement of annual and long-term performance goals, and align employee and investor interests through long-term incentives while managing share usage and equity dilution.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 87,055,111 | 3,491,326 | 577,257 | 96.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 96.14%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christopher MartinIndependent · Nominating & Corporate Governance | $4,712 | — | $700,000 | — | — | $704,712 |
| Peter Thompson, M.DNot independent | 80,000 | — | 304,477 | — | — | 384,477 |
| Laura BregeIndependent · Audit (Chair) · Compensation | 67,500 | — | 304,477 | — | — | 371,977 |
| Arlene M. MorrisIndependent · Audit · Compensation | 57,500 | — | 304,477 | — | — | 361,977 |
| Jonathan Root, M.DIndependent · Audit · Nominating & Corporate Governance (Chair) | 55,000 | — | 304,477 | — | — | 359,477 |
| Badreddin Edris, Ph.DIndependent · Compensation (Chair) | 55,000 | — | 304,477 | — | — | 359,477 |
| Jonathan C. Fox, M.D., Ph.DIndependent · Audit | 45,000 | — | 304,477 | — | — | 349,477 |
| Badreddin EdrisIndependent | 55,000 | — | — | — | — | 55,000 |
| Kevin Koch, Ph.DEmployee director | — | — | — | — | — | 0 |
| Alan Russell, Ph.DEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $419,712 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $419,712 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Edgewise Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Edgewise Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Avidity Biosciences | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 3 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 4 | Protagonist Therapeutics | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 5 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 6 | IDEAYA Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 7 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 8 | Edgewise Therapeutics | 2025 | Kevin Koch | 670,000 | 1,171,625 | 5,041,621 | 462,300 | 7,359,546 |
| 9 | Beam Therapeutics | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 10 | Pliant Therapeutics | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 11 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 12 | Rocket Pharmaceuticals | 2025 | Gaurav Shah | 671,076 | 806,751 | 1,613,377 | 403,048 | 3,510,241 |
| 13 | Keros Therapeutics | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 14 | Dyne Therapeutics | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 15 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
| — | Aerovate Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Enliven Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Edgewise Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Aerovate Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Avidity Biosciences | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine Rewards, LLC |
| Beam Therapeutics | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dyne Therapeutics | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Enliven Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| IDEAYA Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Keros Therapeutics | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Pliant Therapeutics | 50% | Options 67 · RSU 33 | not disclosed | Alpine Rewards |
| Protagonist Therapeutics | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Rocket Pharmaceuticals | not disclosed | not disclosed | not disclosed | Semler Brossy |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kevin Koch | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Executive Compensation”. As printed: 7,359,546. Filing ↗ |
| 2 | Section 01, Robert Blaustein | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Executive Compensation”. As printed: 4,567,385. Filing ↗ |
| 3 | Section 01, Michael Nofi | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Executive Compensation”. As printed: 4,284,659. Filing ↗ |
| 4 | Section 01, Behrad Derakhshan | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Executive Compensation”. As printed: 2,933,228. Filing ↗ |
| 5 | Section 01, Joanne Donovan | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Executive Compensation”. As printed: 2,785,306. Filing ↗ |
| 6 | Section 01, Alan Russell | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Executive Compensation”. As printed: 2,734,849. Filing ↗ |
| 7 | Section 01, R. Michael Carruthers | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Executive Compensation”. As printed: 2,587,465. Filing ↗ |
| 8 | Section 08, Christopher Martin | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 704,712. Filing ↗machine: span 331945–332128 |
| 9 | Section 08, Peter Thompson, M.D | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 384,477. Filing ↗machine: span 324323–324506 |
| 10 | Section 08, Laura Brege | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 371,977. Filing ↗machine: span 326107–326290 |
| 11 | Section 08, Arlene M. Morris | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 361,977. Filing ↗machine: span 333802–333985 |
| 12 | Section 08, Jonathan Root, M.D | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 359,477. Filing ↗machine: span 335965–336148 |
| 13 | Section 08, Badreddin Edris, Ph.D | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 359,477. Filing ↗machine: span 328035–328218 |
| 14 | Section 08, Jonathan C. Fox, M.D., Ph.D | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 349,477. Filing ↗machine: span 329836–330019 |
| 15 | Section 08, Badreddin Edris | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 55,000. Filing ↗machine: span 326932–327114 |
| 16 | Section 08, Kevin Koch, Ph.D | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 08, Alan Russell, Ph.D | DEF 14A | 2026-04-23 | 0001104659-26-047688 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 06, 2026 vote | Form 8-K | 2026-06-05 | 0001104659-26-071011 | Item 5.07 · say-on-pay result. As reported: 96.14% (votes for as printed: 87,055,111). Filing ↗ |
| 19 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 20 | Section 09b board cost (computed) | Computed | — | computed | Cash 419,712 + equity 0 + all other 0 = 419,712, summed across the director compensation table rows.machine: formula: Σ = 419,712 |
| 21 | Cogent Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 22 | Avidity Biosciences, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001599901-25-000092 | CEO total compensation as printed in Avidity Biosciences's own proxy. As printed: 14,176,480. Filing ↗machine: r2 · c48 · span 430390–430400 |
| 23 | Janux Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187095 | CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 24 | Protagonist Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050429 | CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. Filing ↗machine: r1 · c47 · span 613195–613205 |
| 25 | Arcus Biosciences, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 26 | IDEAYA Biosciences, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191501 | CEO total compensation as printed in IDEAYA Biosciences's own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319 |
| 27 | Kymera Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 28 | Edgewise Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047688 | CEO total compensation as printed in Edgewise Therapeutics's own proxy. As printed: 7,359,546. Filing ↗ |
| 29 | Beam Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 30 | Pliant Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 31 | Denali Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 32 | Rocket Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013335 | CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. Filing ↗machine: r2 · c24 · span 348766–348775 |
| 33 | Keros Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046791 | CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. Filing ↗machine: r1 · c41 · span 627980–627989 |
| 34 | Dyne Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173655 | CEO total compensation as printed in Dyne Therapeutics's own proxy. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248 |
| 35 | Zentalis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001725160-26-000027 | CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357 |
| 36 | Section 10a, Cogent Biosciences reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 37 | Section 10a, Janux Therapeutics reciprocity | DEF 14A | — | 0001193125-26-187095 | Janux Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 38 | Section 10a, Pliant Therapeutics reciprocity | DEF 14A | — | 0001746473-26-000076 | Pliant Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 39 | Section 10a, Avidity Biosciences reciprocity | DEF 14A | — | 0001599901-25-000092 | Avidity Biosciences's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 40 | Section 10a, Protagonist Therapeutics reciprocity | DEF 14A | — | 0001104659-26-050429 | Protagonist Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 41 | Section 10a, IDEAYA Biosciences reciprocity | DEF 14A | — | 0001193125-26-191501 | IDEAYA Biosciences's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 42 | Section 10a, Dyne Therapeutics reciprocity | DEF 14A | — | 0001193125-26-173655 | Dyne Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 43 | Section 10a, Kymera Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 44 | Section 10a, Denali Therapeutics reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 45 | Section 10a, Keros Therapeutics reciprocity | DEF 14A | — | 0001104659-26-046791 | Keros Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |
| 46 | Section 10a, Beam Therapeutics reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. Filing ↗ |